Adalank Dosage Guide: Protocols, Calculator & Safety

Dose Range

200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily

Frequency

Once or twice daily during cycles. Every-other-day protocols also documented.

Cycle Length

21-30 day cycles, with 7-14 day washouts between cycles. Avoid chronic continuous dosing.

Half-Life

The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data.

Adalank is itself a stack (Adamax + Selank chemistry in one molecule), so additional stacking should be done conservatively to avoid receptor-level overlap.

Reasonable pairings:

• Cerebrolysin — neurotrophic amplification. The peptide fragment mix in Cerebrolysin layers cleanly on top of Adalank's BDNF/TrkB signal without direct receptor overlap.
• Dihexa — angiotensin-IV-derived synaptogenic. Complementary mechanism (HGF signaling) rather than overlapping with the BDNF or GABA pathways Adalank already covers.
• BPC-157 — neuroprotective baseline. Pairs with cognitive enhancers via dopaminergic system stabilization. No mechanistic overlap.
• Methylene Blue — mitochondrial cofactor for general cognitive support. Different mechanism layer.

Avoid stacking with:

• Adamax — Adalank already contains the Adamax pharmacophore. Stacking is redundant and risks D2 desensitization.
• Selank — same reason: Adalank already contains the Selank pharmacophore.
• Semax, N-Acetyl Semax Amidate, P-21 — overlapping BDNF / TrkB / D2 signaling. Use one or the other.
• Benzodiazepines — additive GABAergic effects, potential for impaired alertness and inverted "alert calm" profile.

Cycle architecture:

Recommended 30-day cycles followed by 14-day washouts. Avoid chronic continuous dosing — receptor desensitization at both the BDNF/TrkB and GABAergic ends is a theoretical concern given the multi-mechanism profile, and there is no long-term safety data to draw on.

Adalank dosing follows a similar pattern to Selank and Adamax — micrograms, not milligrams. Vendor product labeling varies; double-check vial concentration before reconstitution because the hybrid molecule can be sold at concentrations between Selank (5-10 mg vials) and Adamax (2-10 mg vials).

Intranasal protocol (most common):

• Reconstitute lyophilized peptide in bacteriostatic water to a known concentration (often 100 mcg per spray when properly mixed)
• 2-4 sprays per session, once or twice daily during cycles
• Effects build over 7-10 days; subjective peak is typically reported in weeks 2-3 of a cycle

Subcutaneous protocol (less common but documented):

• 200-1200 mcg per injection, 1-2x daily
• Faster onset than intranasal but the duration of effect is similar given the hybrid molecule's claimed extended receptor binding

What to avoid:

• Late-evening dosing (the Adamax component can disrupt sleep at higher doses)
• Continuous chronic dosing without washouts (receptor desensitization is a theoretical concern given the multi-mechanism profile)
• Combining at full doses with overlapping family compounds (Semax, Selank, Adamax, P-21)

Stability: After reconstitution, store in the refrigerator and use within 28 days. Adalank should not be frozen post-reconstitution — repeated freeze-thaw cycles degrade the peptide bonds.